乳児てんかん性スパズム治療の世界市場

乳児てんかん性スパズム治療の世界市場は2030年までに38億米ドルに達する見込み

2024年に32億米ドルと推定される乳児てんかん性スパズム治療の世界市場は、分析期間2024-2030年にCAGR 2.9%で成長し、2030年には38億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗けいれん薬は、CAGR 2.7％を記録し、分析期間終了時には23億米ドルに達すると予測されます。副腎皮質ステロイドの成長率は、分析期間中CAGR 3.5%と推定されます。

米国市場は8億7,880万米ドルと推定、中国はCAGR 5.4％で成長予測

米国の乳児てんかん性スパズム治療市場は、2024年に8億7,880万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億4,370万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.1%と2.2%と予測されています。欧州では、ドイツがCAGR 1.6%で成長すると予測されています。

世界の乳児てんかん性スパズム治療市場- 主要動向と促進要因まとめ

小児けいれんが緊急の治療課題として浮上しているのはなぜか？

臨床的にはウエスト症候群としても知られる小児けいれんは、その壊滅的な発達上の影響、複雑な神経生理学、そして診断上の警戒心の向上による認知度の高まりから、小児神経学の最前線に躍り出た。この疾患は典型的には生後1年以内に発症し、発達停止や退行が否定できなくなるまで、良性の驚愕反射、胃食道逆流姿勢、あるいは単純なミオクロニー発作と間違われやすい、短時間だが爆発的な軸索収縮のクラスターを呈します。神経生理学者は現在、不整脈と呼ばれる明らかにカオス的な脳波の徴候を認識しており、新生児集中治療環境におけるビデオ脳波モニタリング装置の普及により、早期発見が可能になっています。疫学的データでは、出生1万人あたりおよそ2～4例の発生が示唆されているが、周産期の低酸素性虚血障害、結節性硬化症、出生前感染症などの発生率が高い地域では、有病率は増幅されます。痙攣が未治療または最適に管理されていない場合、認知障害、難治性てんかん、自閉症スペクトラムの行動へと急速に進行するため、神経発達を維持するためには迅速な治療介入が不可欠です。介護者支援団体やソーシャルメディアコミュニティは、突然のアイコンタクトの喪失、発達の停滞、壊滅的な脳波所見を訴える両親の声を増幅させ、プライマリケアから小児てんかん専門医への紹介時間を短縮するよう医療制度に迫っています。その結果、臨床家は現在、症状発現から数カ月ではなく数日以内に疾患修飾療法を開始する倫理的・物流的要請に直面しており、治療パラダイムを再構築し、乳児てんかん性スパズム治療を公衆衛生の優先事項へと高めています。

科学的革新は、従来のホルモン療法を超える治療成果をもたらすか？

現代の小児けいれんの管理は、副腎皮質刺激ホルモンと経口コルチコステロイドを中心とした従来のプロトコールをはるかに超えて進化しています。両者ともけいれんを終息させることができるが、高血圧、免疫抑制、可逆的脳萎縮のリスクを伴う。精密薬理学は、γ-アミノ酪酸トランスアミナーゼの選択的非可逆的阻害剤であるビガバトリンを、結節性硬化症に伴う痙攣に対する第一選択薬として、また隠微な症例における重要な第二選択薬として導入しました。現在進行中の第III相試験では、ビガバトリンの高累積投与でみられる有名な合併症である不可逆的視野欠損を最小限に抑えつつ、発作抑制を維持する次世代GABA作動性類似薬が評価されています。また、シナプスおよびシナプス外GABA-A受容体を調節する合成神経ステロイドであるガナキソロンも評価されており、プレドニゾロンとの併用で有望な非盲検有効性が示されています。また、エベロリムスのようなmTOR経路阻害薬は、結節性硬化症に関連したてんかん発症の根底にある上流の調節障害に対処するために、腫瘍学から再利用されつつあります。遺伝子特異的治療に対する関心は高まっており、CDKL5欠損症やSTXBP1脳症に対するアンチセンスオリゴヌクレオチドが検討されています。神経調節戦略も進歩しています。乳児に対する反応性神経刺激はまだ実験的であるが、視床中部の視床核を標的とした脳深部刺激は、同情的使用プログラムに入っています。栄養療法も厳密な精査を受けています。中鎖トリグリセリドを正確に調整した改良型ケトジェニック・プロトコールは、古典的なケトジェニック食の代謝負担を軽減しながら、痙攣の軽減を実証しています。これらの科学的進歩を総合すると、けいれんの終息だけでなく、その根底にある神経発達の軌跡を変化させることを目的とした多次元的な治療法が生まれつつあり、小児けいれん治療における精密性と個別化の新時代の到来を予感させる。

規制、経済、介護者の要因は、治療法の採用と利用しやすさにどのように影響するか？

乳児てんかん性スパズム治療における実験室での画期的な発見からベッドサイドでのインパクトまでの経路は、規制の枠組み、支払者の決定、そして介護者の生活実態に強く媒介されています。米国、欧州、日本において乳児てんかん性スパズム治療が希少疾病用医薬品に指定されると、市場独占権、税制優遇措置、審査期間の短縮が与えられ、革新的な薬剤の参入が加速されるが、その結果、発売価格が割高になることが多いです。費用便益分析によれば、早期に発作をコントロールすることで、集中的な発達療法や特別支援教育サービスを減らすことができ、長期的な節約になることが明らかになっています。多くの低資源環境では、ACTHの入手は依然として生物活性が変化する配合剤に限られており、一方、ビガバトリン錠剤は、人道的な調達ルートがなければ、しばしば品切れとなったり、手が届かなかったりします。遠隔神経学プラットフォームは、地域の病院と三次てんかんセンターをつなぎ、脳波の迅速な判読と治療開始の推奨を行うことで、地理的なギャップを埋め始めているが、ブロードバンドの普及率と臨床医の帯域幅が依然として制限要因となっています。介護者は、複雑なステロイド漸減スケジュール、注意深い血圧モニタリング、毎月の眼科検査などをこなしながら、治療アドヒアランスに大きな役割を果たしています。多言語による教育ツールキット、テキストメッセージによるリマインダーシステム、ピアメンタープログラムは、治療開始後の重要な6ヶ月間のアドヒアランス維持に有効であることが証明されています。倫理委員会や患者擁護委員会は、発作指標と並んで神経発達のエンドポイントを含めるよう要求することで、試験デザインに影響を与え、発達のQOLを考慮した規制当局の承認を確実なものにしています。これらの非臨床的な力を総称して、市場への浸透と治療の公平性が形成され、画期的な科学が、集団レベルのインパクトを達成するためには、政策の革新や介護者の関与と組み合わされる必要があることが強調されています。

乳児てんかん性スパズム治療市場の成長加速の原動力は？

乳児てんかん性スパズム治療市場の成長は、診断の鋭敏化、遺伝学的知見の拡大、先進的な償還政策、管理可能な安全性プロファイルで優れた有効性を約束する標的療法の強固なパイプラインに根ざしたいくつかの要因によって牽引されています。第一に、新生児保育所や救急部における高解像度ビデオ脳波モニタリングの普及により、痙攣の早期発見が可能となり、治療可能な集団が拡大し、速効性薬剤の価値が強調されています。第二に、次世代シークエンシング・パネルにより、予後を明らかにするだけでなく、分子レベルでの治療介入を可能にする病原性変異が発見され、遺伝子特異的治療薬やコンパニオン診断薬への投資が加速しています。第三に、希少疾病用医薬品の優遇措置と小児優先審査バウチャーが商業的リスクを低下させ、バイオテクノロジー企業がアンメットニーズの高い少人数適応症を追求することを奨励しています。第四に、全国てんかん登録から得られた実データが、早期介入により認知機能が改善するという有力なエビデンスを提供しているため、保険会社や国の医療サービスは、割高な治療費を払い戻し、在宅ステロイド投与プログラムにも資金を提供しています。第五に、製薬企業とてんかんセンターとの戦略的提携により、適応試験デザインを通じて第Ⅱ相臨床試験が効率化され、厳密性を損なうことなく開発期間が短縮されています。第6に、介護者支援ネットワークの普及は、一般の人々の認知度を高め、研究のための資金調達を促進し、医薬品の輸入やコンパッショネートユースアクセスを促進する政策改革を促しています。第7に、発作を検知するウェアラブル端末とAIを活用した投薬アルゴリズムを統合した新たなデジタル治療薬が、薬物療法を補完し、付随的な収益源を開拓し、市場全体のエコシステムを強化する態勢を整えています。これらの連動した推進力により、乳児てんかん性スパズム治療は、ニッチなサブスペシャリティの関心事から、小児神経科学イノベーションの活気に満ちた急成長領域へと変貌を遂げ、世界中の患児の生存、認知、QOLに有意義な改善をもたらす態勢が整いつつあります。

セグメント

治療クラス（抗けいれん薬、副腎皮質ステロイド、その他の薬剤クラス別）;薬剤タイプ（ビガバトリン、副腎皮質刺激ホルモン、その他の薬剤タイプ）;用法用量（固形剤、液体剤）

調査対象企業の例

• Amneal Pharmaceuticals
• ANI Pharmaceuticals
• Biocodex SA
• Boehringer Ingelheim
• Catalyst Pharmaceuticals
• Cipla Limited
• Currax Pharmaceuticals LLC
• Dr. Reddy's Laboratories Ltd.
• GW Pharmaceuticals（Jazz Pharma）
• Hikma Pharmaceuticals Plc
• Ionis Pharmaceuticals
• Lupin Limited
• Mallinckrodt Pharmaceuticals
• Marinus Pharmaceuticals
• Medexus Pharmaceuticals Inc.
• Mylan（Viatris Inc.）
• Novartis AG
• Orion Corporation
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Infantile Spasm Therapeutics Market to Reach US$3.8 Billion by 2030

The global market for Infantile Spasm Therapeutics estimated at US$3.2 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Anticonvulsants, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Corticosteroids segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$878.8 Million While China is Forecast to Grow at 5.4% CAGR

The Infantile Spasm Therapeutics market in the U.S. is estimated at US$878.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$743.7 Million by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Infantile Spasm Therapeutics Market - Key Trends & Drivers Summarized

Why Is Infantile Spasm Emerging as an Urgent Therapeutic Priority?

Infantile spasm, also known clinically as West syndrome, has moved to the forefront of pediatric neurology because of its devastating developmental consequences, its complex neurophysiology, and its increasing visibility through improved diagnostic vigilance. The disorder typically strikes within the first year of life, presenting with clusters of brief but explosive axial contractions that are easily mistaken for benign startle reflexes, gastroesophageal reflux posturing, or simple myoclonic jerks until developmental arrest or regression becomes undeniable. Neurophysiologists now recognize a distinctly chaotic electroencephalographic signature called hypsarrhythmia, and widespread deployment of video EEG monitoring units in neonatal intensive care settings is driving earlier detection. Epidemiological data suggest an incidence of roughly two to four cases per ten thousand live births, yet prevalence is amplified in regions with high rates of perinatal hypoxic-ischemic injury, tuberous sclerosis complex, or prenatal infections-all factors that remain stubbornly common in many low-- and middle-income countries. Untreated or suboptimally managed spasms progress rapidly to cognitive impairment, refractory epilepsy, and autism-spectrum behaviors, making prompt therapeutic intervention essential for neurodevelopmental preservation. Caregiver advocacy groups and social media communities have amplified the voices of parents who describe sudden loss of eye contact, developmental plateau, and catastrophic EEG findings, pressing health systems to shorten referral times from primary care to pediatric epilepsy specialists. Consequently, clinicians now face both ethical and logistical imperatives to initiate disease-modifying therapy within days rather than months of symptom onset, reshaping treatment paradigms and elevating infantile spasm therapeutics to a public health priority.

Can Scientific Innovation Transform Treatment Outcomes Beyond Traditional Hormonal Protocols?

Contemporary management of infantile spasm is evolving well beyond legacy protocols centered on adrenocorticotropic hormone and oral corticosteroids, both of which can terminate spasms but carry risks of hypertension, immunosuppression, and reversible brain atrophy. Precision pharmacology has introduced vigabatrin, a selective irreversible inhibitor of gamma-aminobutyric-acid transaminase, as the first-line option for spasms associated with tuberous sclerosis complex and as a key second-line therapy in cryptogenic cases. Ongoing phase III trials are evaluating next-generation GABA-ergic analogues that maintain seizure suppression while minimizing irreversible visual field defects, a notorious complication seen with high cumulative vigabatrin exposure. Investigators are also assessing ganaxolone, a synthetic neurosteroid modulating synaptic and extrasynaptic GABA-A receptors, which has shown promising open-label efficacy when combined with prednisolone. Elsewhere, mTOR pathway inhibitors such as everolimus are being repurposed from oncology to address the upstream dysregulation underlying tuberous sclerosis-related epileptogenesis, offering a disease-targeted alternative rather than purely symptomatic control. Interest in gene-specific therapies is mounting, with antisense oligonucleotides being explored for CDKL5 deficiency and STXBP1 encephalopathy, both high-risk genotypes for early infantile spasms. Neuromodulation strategies are advancing as well: responsive neurostimulation for infants remains experimental, but deep brain stimulation targeting the centromedian thalamic nucleus has entered compassionate-use programs. Nutritional therapies are also under rigorous scrutiny; modified ketogenic protocols with precisely titrated medium-chain triglycerides are demonstrating spasm reduction while mitigating the metabolic burden of classic ketogenic diets. Collectively, these scientific advances are creating a multidimensional therapeutic landscape aimed not only at terminating spasms but also at altering the underlying neurodevelopmental trajectory, heralding a new era of precision and personalization in infantile spasm care.

How Do Regulatory, Economic, and Caregiver Factors Influence Therapy Adoption and Accessibility?

The pathway from laboratory breakthrough to bedside impact in infantile spasm therapeutics is strongly mediated by regulatory frameworks, payer decisions, and the lived realities of caregivers. Designation of infantile spasm treatments as orphan drugs in the United States, Europe, and Japan confers market exclusivity, tax incentives, and abbreviated review timelines, accelerating entry of innovative agents yet often resulting in premium launch prices. Cost-utility analyses reveal that early seizure control yields long-term savings by reducing intensive developmental therapies and special-education services, prompting some national health authorities to reimburse expensive biologics when robust real-world evidence supports durable cognitive gains. Still, disparities persist: in many low-resource settings, availability of ACTH remains limited to compounded formulations with variable bioactivity, while vigabatrin tablets are frequently out of stock or unaffordable without humanitarian procurement channels. Tele-neurology platforms are beginning to bridge geographic gaps by connecting regional hospitals to tertiary epilepsy centers for rapid EEG interpretation and treatment initiation recommendations, although broadband penetration and clinician bandwidth remain limiting factors. Caregivers play an outsized role in treatment adherence, juggling complex steroid taper schedules, vigilant blood-pressure monitoring, and monthly ophthalmologic exams. Educational toolkits in multiple languages, text-message reminder systems, and peer-mentor programs have proven effective in sustaining adherence during the critical six-month consolidation window that follows therapy onset. Ethics committees and patient-advocacy councils influence trial design by demanding inclusion of neurodevelopmental endpoints alongside seizure metrics, ensuring that developmental quality-of-life considerations guide regulatory approvals. Collectively, these non-clinical forces shape market penetration and therapeutic equity, underscoring that breakthrough science must be paired with policy innovation and caregiver engagement to achieve population-level impact.

What Is Driving the Accelerated Growth of the Infantile Spasm Therapeutics Market?

The growth in the infantile spasm therapeutics market is driven by several factors rooted in heightened diagnostic acuity, expanding genetic insights, progressive reimbursement policies, and a robust pipeline of targeted therapies that promise superior efficacy with manageable safety profiles. First, widespread adoption of high-resolution video EEG monitoring in newborn nurseries and emergency departments is identifying spasms earlier, enlarging the treatable population and emphasizing the value of rapid-acting agents. Second, next-generation sequencing panels are unmasking pathogenic variants that not only clarify prognosis but also point toward molecularly tailored interventions, accelerating investment in gene-specific therapeutics and companion diagnostics. Third, orphan-drug incentives and pediatric priority review vouchers are lowering commercial risk, encouraging biotech firms to pursue small-population indications with high unmet need. Fourth, real-world data from national epilepsy registries are providing compelling evidence that early intervention improves cognitive trajectories, prompting insurers and national health services to reimburse premium therapies and even fund home-based steroid administration programs. Fifth, strategic collaborations between pharmaceutical companies and academic epilepsy centers are streamlining phase II proof-of-concept studies through adaptive trial designs, shortening development timelines without compromising rigor. Sixth, the proliferation of caregiver advocacy networks is boosting public awareness, driving fundraising for research, and catalyzing policy reforms that facilitate medication importation and compassionate-use access. Seventh, emerging digital therapeutics that integrate seizure-detection wearables and AI-driven dosing algorithms are poised to complement pharmacologic regimens, opening ancillary revenue streams and reinforcing the overall market ecosystem. These interlocking drivers are collectively transforming infantile spasm therapeutics from a niche subspecialty concern into a vibrant, fast-growing domain of pediatric neuroscience innovation poised to deliver meaningful improvements in survival, cognition, and quality of life for affected infants worldwide.

SCOPE OF STUDY:

The report analyzes the Infantile Spasm Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutic Class (Anticonvulsants, Corticosteroids, Other Therapeutic Classes); Drug Type (Vigabatrin, Adrenocorticotropic Hormone, Other Drug Types); Dosage (Solid Dosage, Liquid Dosage)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• Amneal Pharmaceuticals
• ANI Pharmaceuticals
• Biocodex SA
• Boehringer Ingelheim
• Catalyst Pharmaceuticals
• Cipla Limited
• Currax Pharmaceuticals LLC
• Dr. Reddy's Laboratories Ltd.
• GW Pharmaceuticals (Jazz Pharma)
• Hikma Pharmaceuticals Plc
• Ionis Pharmaceuticals
• Lupin Limited
• Mallinckrodt Pharmaceuticals
• Marinus Pharmaceuticals
• Medexus Pharmaceuticals Inc.
• Mylan (Viatris Inc.)
• Novartis AG
• Orion Corporation
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Infantile Spasm Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Diagnosis Rates and Early Intervention Efforts Throw the Spotlight on Infantile Spasm Therapeutics as a Critical Segment in Pediatric Neurology
  • Increasing Awareness Among Pediatricians and Neurologists Propels Demand for Timely and Evidence-Based Treatment Approaches
  • Here's the Story: Clinical Guidelines Emphasizing Early Treatment Strengthen the Business Case for First-Line Therapeutics
  • Advances in Neuroimaging and EEG Technologies Drive Earlier and More Accurate Identification of Infantile Spasms
  • Growing Pipeline of ACTH Analogs, Steroids, and Antiepileptic Drugs Supports Innovation in Drug Formulations and Dosing Regimens
  • Here's How Research in Genetic and Metabolic Causes of Infantile Spasms Is Opening Doors to Targeted Therapies
  • Rising Focus on Neurodevelopmental Outcomes Fuels Demand for Fast-Acting and Tolerable Therapeutic Options
  • Global Expansion of Pediatric Specialty Clinics Enhances Access to Infantile Spasm Treatment in Urban and Semi-Urban Areas
  • Growth in Specialty Pharmaceuticals and Orphan Drug Designation Accelerates R&D and Market Entry of Novel Therapeutics
  • Emergence of Precision Medicine and Genetic Screening Fuels Long-Term Potential for Personalized Infantile Spasm Therapies
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Infantile Spasm Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Infantile Spasm Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Vigabatrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Vigabatrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Vigabatrin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Adrenocorticotropic Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Adrenocorticotropic Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Adrenocorticotropic Hormone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Solid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Solid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Solid Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Liquid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Liquid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Liquid Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• JAPAN
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Japan 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• CHINA
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: China 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: China 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: China 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• EUROPE
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Infantile Spasm Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Europe 16-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Europe 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• FRANCE
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 77: France Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: France 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: France 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: France 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• GERMANY
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Germany 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Germany 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Italy 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Italy 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 104: UK Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: UK 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: UK 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Spain 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Spain 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Russia 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Russia 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Australia 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Australia 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• INDIA
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 161: India Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: India 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: India 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: India 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: South Korea 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: South Korea 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Infantile Spasm Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Argentina 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Argentina 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Brazil 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Brazil 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Mexico 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Mexico 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Infantile Spasm Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Iran 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Iran 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Israel 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Israel 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: UAE 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: UAE 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
• AFRICA
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Africa 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Africa 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030

IV. COMPETITION